1. BioMed Pharma, along with its parent company, is a market leader in oncology and biologic medicines, supported by over a decade of commercial expertise and a robust long-term strategy to achieve sustainable growth.

2. Future growth will be driven by strategic expansion into key areas such as biosimilars, oncology, immunology, and diabetic treatments.

3. As a pioneering company, BioMed Pharma is at the forefront of enhancing access to and promoting the adoption of biosimilars in Yemen.

4. Biosimilars are poised to become the company’s primary growth driver. BioMed Pharma is committed to establishing strong partnerships in this segment to ensure sustainable market leadership.

5. Yemen’s pharmaceutical market presents significant opportunities, supported by increasing engagement from the government and international agencies to enhance patient care.

6. While generics will continue to underpin core market growth in Yemen, the biosimilar segment is anticipated to experience rapid acceleration, driving transformative growth.